Spots Global Cancer Trial Database for PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor
Official Title: A Clinical Study of PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor
Study ID: NCT02873390
Interventions
Study Description
Brief Summary: To evaluate the safety and effectiveness of cell therapy using herinCAR-PD1 cells to treat advanced cancer. Individuals greater than or equal to 18 years of age and less than or equal to 70 years of age who have been diagnosed with relapsed or refractory cancer that has not responded to or has relapsed after standard treatment.
Detailed Description: A total of 20 patients may be enrolled over a period of 1-2 years.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Ningbo No.5 Hospital (Ningbo Cancer Hospital), Ningbo, Zhejiang, China
Contact Details
Name: Jiangtao Wang
Affiliation: Ningbo No.5 Hospital (Ningbo Cancer Hospital)
Role: STUDY_DIRECTOR
Name: Huajun Jin
Affiliation: Shanghai Cell Therapy Research Institute
Role: STUDY_CHAIR
Name: Qijun Qian
Affiliation: Shanghai Cell Therapy Research Institute
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
